Intellia has leveraged its expertise in Crispr/Cas9 gene editing to advance a pipeline of in vivo and ex vivo therapies for diseases with high unmet medical needs. We believe Intellia's proprietary ...

In a 2014 Nature paper, Ralston described this awkward process — trogocytosis, or “cell nibbling.” It was a revelation at the ...

Researchers at the Max Planck Institute for Evolutionary Anthropology have addressed a longstanding challenge in CRISPR ...